復星醫藥(600196.SH):漢斯狀®聯合HLX07和漢貝泰®用於一線治療不可切除或轉移性肝細胞癌(HCC)獲批內地臨牀試驗
格隆匯4月20日丨復星醫藥(600196.SH)公佈,近日,公司控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司上海復宏漢霖生物製藥有限公司(合稱“復宏漢霖”)收到國家藥監局關於同意其自主研發的漢斯狀®(斯魯利單抗注射液)聯合重組抗EGFR人源化單克隆抗體注射液(簡稱“HLX07”)、聯合漢貝泰®(貝伐珠單抗注射液)用於一線治療不可切除或轉移性肝細胞癌(HCC)(簡稱“該治療方案”)開展臨牀試驗的批准。復宏漢霖擬於條件具備後於中國內地開展該治療方案的II期臨牀試驗。
截至該公吿日,於全球範圍內尚無同類聯合用藥治療方案獲上市批准。截至2022年3月,集團現階段針對該治療方案的累計研發投入為人民幣25萬元(未經審計;不包含單藥)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.